This activity focuses on High-Risk Scenarios and Prevention of Complications in the cardiac catheterization laboratory (CCL), reviewing system processes and protocols to assist in mitigating adverse events and improving outcomes in the CCL. The faculty will discuss implementing best practices for femoral arterial access in the era of radial access, management of coronary artery perforation and aortocoronary/ascending aorta dissections, and how to approach a patient with a recent stroke needing to go to the CCL.

Moderator: Emmanouil S. Brilakis, MD, PhD, FSCAI 
Q&A Moderator: William W. O’Neill, MD, MSCAI

•    Processes to Prepare Staff for the Management of Cath Lab Disasters, Joaquin E. Cigarroa, MD, FSCAI
•    Optimizing Femoral Access in a Radial First Lab, Javier Alfonso Valle, MD
•    Avoiding Coronary Artery Perforation and How to Manage When They Occur, Yader B. Sandoval, MD, FSCAI
•    Patient With a Recent Stroke: Is It Safe to Go to the Cath Lab and if so, When?, Deepali Nivas Tukaye, MBBS, FSCAI
•    Minimizing Risk for Aortocoronary Dissection in the Cath Lab and How to Manage When They Occur, Konstantinos Charitakis, MD, FSCAI

After completing this webinar, participants will be able to:

As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities. All participating faculty, course directors, planning committee members and staff are required to disclose to SCAI any relevant financial relationships. SCAI identifies relevant conflicts of interest and mitigates those conflicts before the activity begins.

Planning Process: SCAI activities are developed by the SCAI Planners prior to and independent of commercial support. Members of the Planning Committee reviewed and approved this activity, and those with relevant conflicts of interest recused themselves. Members of SCAI’s Continuing Medical Education Oversight Committee, clinicians in the field of cardiac catheterization and angiography, reviewed all educational materials and verified that the materials are fair, accurate, and free of commercial bias.

Content Validation Statement: 

As a provider of continuing medical education through the Accreditation Council for Continuing Medical Education (ACCME), it is the Society’s policy to ensure balance, independence, objectivity, and scientific rigor in all its activities. All participating faculty, course directors, planning committee members and staff are required to disclose to SCAI any relevant financial relationships. SCAI identifies relevant conflicts of interest and mitigates those conflicts before the activity begins.

Planning Process: SCAI activities are developed by the SCAI Planners prior to and independent of commercial support. Members of the Planning Committee reviewed and approved this activity, and those with relevant conflicts of interest recused themselves. Members of SCAI’s Continuing Medical Education Oversight Committee, clinicians in the field of cardiac catheterization and angiography, reviewed all educational materials and verified that the materials are fair, accurate, and free of commercial bias.

Content Validation Statement: 
SCAI accepts the following Content Validation Statements and expects all persons involved in its professional education activities to abide by these statements for clinical care recommendations. All clinical and pharmacological recommendations are based on evidence accepted within the medical profession as adequate jurisdiction for their indications and contradictions in patient care. All research referenced to support or justify patient care recommendations conforms to accepted standards of experimental design, data collection and analysis.

SCAI's educational content is free of marketing or sales of products or services. Faculty will not actively promote or sell products or services that serve their professional or financial interests during accredited education. 

SCAI encourages faculty to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

© 2021-2022 Society for Cardiovascular Angiography and Interventions (SCAI). All rights reserved.